• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4658978)   Today's Articles (4159)   Subscriber (51286)
For: Hock BD, Mckenzie JL, Goddard L, Smith SM, Mcentyre CJ, Keating PE. Discrimination of Anti-drug Antibodies With Neutralizing Capacity in Infliximab- and Adalimumab-Treated Patients: Comparison of the Homogeneous Mobility Shift Assay and the Affinity Capture and Elution Assay. Ther Drug Monit 2018;40:705-15. [DOI: 10.1097/ftd.0000000000000553] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Number Cited by Other Article(s)
1
Di Santo A, Accinno M, Errante F, Capone M, Vultaggio A, Simoncini E, Zipoli G, Cosmi L, Annunziato F, Rovero P, Real Fernandez F. Quantitative evaluation of adalimumab and anti-adalimumab antibodies in sera using a surface plasmon resonance biosensor. Clin Biochem 2024;133-134:110838. [PMID: 39489392 DOI: 10.1016/j.clinbiochem.2024.110838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2024] [Revised: 10/10/2024] [Accepted: 10/30/2024] [Indexed: 11/05/2024]
2
Keating PE, Hock BD, Chin PKL, O'Donnell JL, Barclay ML. Evaluation of the Homogenous Mobility Shift Assay for Infliximab and Adalimumab Anti-drug Antibody Detection in the Clinical Laboratory. Ther Drug Monit 2024;46:619-626. [PMID: 38648648 DOI: 10.1097/ftd.0000000000001200] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2023] [Accepted: 02/08/2024] [Indexed: 04/25/2024]
3
Stamp LK, Keating P, Frampton C, Barclay ML, Fanning N, Millier M, Hessian PA, O'Donnell JL. Relationship Between Adalimumab Concentrations, Antidrug Antibodies, and Disease Activity in Rheumatoid Arthritis: A Cross-Sectional Observational Study. J Rheumatol 2024;51:242-249. [PMID: 38224989 DOI: 10.3899/jrheum.2023-0706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/19/2023] [Indexed: 01/17/2024]
4
Ashby L, Chan L, Winterbourn C, Woon ST, Keating P, Heller R, Ameratunga R, Chua I, Hsiao KC. Phenotypic spectrum in a family with a novel RAC2 p.I21S dominant-activating mutation. Clin Transl Immunology 2024;13:e1493. [PMID: 38410820 PMCID: PMC10895683 DOI: 10.1002/cti2.1493] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2024] [Revised: 02/11/2024] [Accepted: 02/12/2024] [Indexed: 02/28/2024]  Open
5
Keating PE, Hock BD, Smith SM, Chin PKL, O'Donnell JL, Barclay ML. Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing. Intern Med J 2023;53:2123-2127. [PMID: 37997271 DOI: 10.1111/imj.16264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Accepted: 09/12/2023] [Indexed: 11/25/2023]
6
Hock BD, Goddard L, MacPherson SA, Strother M, Gibbs D, Pearson JF, McKenzie JL. Levels and in vitro functional effects of circulating anti-hinge antibodies in melanoma patients receiving the immune checkpoint inhibitor pembrolizumab. PLoS One 2023;18:e0290793. [PMID: 37713423 PMCID: PMC10503750 DOI: 10.1371/journal.pone.0290793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2023] [Accepted: 08/15/2023] [Indexed: 09/17/2023]  Open
7
Megna BW, Vaughn BP. Therapeutic Drug Monitoring in Practice for Inflammatory Bowel Disease. Curr Gastroenterol Rep 2022;24:191-200. [PMID: 36459387 DOI: 10.1007/s11894-022-00854-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/11/2022] [Indexed: 06/17/2023]
8
Barrau M, Duprat M, Veyrard P, Tournier Q, Williet N, Phelip JM, Waeckel L, Cheifetz AS, Papamichael K, Roblin X, Paul S. A Systematic Review on the interest of Drug Tolerant assay in the monitoring of Inflammatory Bowel Disease. J Crohns Colitis 2022;17:633-643. [PMID: 36301958 DOI: 10.1093/ecco-jcc/jjac164] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/05/2022] [Indexed: 02/08/2023]
9
Subtyping anti-infliximab antibodies by the homogenous mobility shift assay (HMSA): potential utility in a pharmacokinetic case study. Pathology 2022;55:587-590. [PMID: 36400595 DOI: 10.1016/j.pathol.2022.08.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2022] [Revised: 07/01/2022] [Accepted: 08/18/2022] [Indexed: 11/07/2022]
10
Assessment of immunogenicity and drug activity in patient sera by flow-induced dispersion analysis. Sci Rep 2022;12:4670. [PMID: 35304547 PMCID: PMC8933425 DOI: 10.1038/s41598-022-08682-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2021] [Accepted: 03/09/2022] [Indexed: 01/20/2023]  Open
11
Suh K, Kyei I, Hage DS. Approaches for the detection and analysis of anti-drug antibodies to biopharmaceuticals: A review. J Sep Sci 2022;45:2077-2092. [PMID: 35230731 DOI: 10.1002/jssc.202200112] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2022] [Revised: 02/10/2022] [Accepted: 02/26/2022] [Indexed: 11/10/2022]
12
Functional effects of immune complexes formed between pembrolizumab and patient-generated anti-drug antibodies. Cancer Immunol Immunother 2020;69:2453-2464. [PMID: 32556495 DOI: 10.1007/s00262-020-02636-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2020] [Accepted: 06/09/2020] [Indexed: 12/19/2022]
13
Keating PE, Duncan R, Spellerberg M, O'Donnell J, Hock BD. Measurement of anti-natalizumab antibodies by homogeneous mobility shift assay. Pathology 2020;52:373-374. [PMID: 32113675 DOI: 10.1016/j.pathol.2020.01.682] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2019] [Revised: 01/16/2020] [Accepted: 01/23/2020] [Indexed: 11/25/2022]
14
Barclay ML, Karim S, Helms ETJ, Keating PE, Hock B, Stamp LK, Schultz M. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays. Intern Med J 2020;49:513-518. [PMID: 30091273 DOI: 10.1111/imj.14064] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2018] [Accepted: 07/30/2018] [Indexed: 11/29/2022]
15
Development of a competitive binding homogeneous mobility shift assay for the quantification of adalimumab levels in patient serum. J Immunol Methods 2019;474:112672. [DOI: 10.1016/j.jim.2019.112672] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2019] [Revised: 08/05/2019] [Accepted: 09/12/2019] [Indexed: 01/20/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA